Evolocumab (AMG 145) (Amgen) PROFICIO (Program to Reduce LDL-C and Cardiovascular Outcomes Following Inhibition of PCSK9 In Different Populations) is the Phase 3 programme evaluating evolocumab in 13 trials, with a combined planned enrolment of more than 28,000 patients. read more »
Alirocumab (SAR236553/REGN727) (Sanofi/Regeneron). Alirocumab is being evaluated in the ODYSSEY clinical trial programme in >23,000 patients in 12 phase 3 trials. read more »
Bococizumab: SPIRE clinical trial programme (terminated).read more »
Phase I study (reformulated) Fitzgerald K, et al. 2014.
read more »